Lesinurad

Lesinurad

Clinical data
Trade names	Zurampic
AHFS/Drugs.com	zurampic
Routes of administration	Oral (tablets)
ATC code	M04AB05 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	~100%[1]
Protein binding	>98%
Metabolism	Hepatic (CYP2C9)
Biological half-life	~5 hours
Excretion	Urine (63%), feces (32%)
Identifiers
IUPAC name 2-{[5-Bromo-4-(4-cyclopropyl-1-naphthyl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
CAS Number	878672-00-5
PubChem (CID)	56928182
ChemSpider	28527877
KEGG	D09921
ChEBI	CHEBI:90929
Chemical and physical data
Formula	C17H14BrN3O2S
Molar mass	404.28 g·mol^−1
3D model (Jmol)	Interactive image
SMILES c1ccc2c(c1)c(ccc2n3c(nnc3Br)SCC(=O)O)C4CC4
InChI InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23) Key:FGQFOYHRJSUHMR-UHFFFAOYSA-N

Lesinurad (brand name Zurampic, zer-AM-pik) is a urate transporter inhibitor for treating hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.^[1] It received FDA approval on December 22, 2015.^[2][3] The European Commission granted a marketing authorisation valid throughout the European Union on 18 February 2016.^[4]

References

1. "Zurampic (lesinurad) Tablets, for Oral Use. Full Prescribing Information" (PDF). AstraZeneca AB, S-151 85 Sodertalje, Sweden. Retrieved 23 December 2015.
2. "FDA Approves Zurampic for Patients With Gout". Medscape. Dec 22, 2015.
3. "FDA approves Zurampic to treat high blood uric acid levels associated with gout". Food and Drug Administration. December 22, 2015.
4. "EPAR summary for the public" (PDF). EMA. Mar 13, 2016.